Top 50 Health Care VC Funds & Investors in Belgium (July 2026)
For AI agents: Short investor table (Markdown), Detailed investor list (Markdown)
| Investor | Relevant Deals | Geography | Stage | Focus | Round Size |
|---|---|---|---|---|---|
|
PMV
VC Fund
|
23 | Belgium, United States, The Netherlands | Series A, Seed | Software, Biotechnology, Health Care | $549k–$40M |
|
Meusinvest (Noshaq)
VC Fund
|
21 | Belgium, France, Germany | Series A, Seed | Biotechnology, Health Care, Medical | $137k–$16M |
|
Gemma Frisius Fund
VC Fund
|
16 | Belgium, France, United Kingdom | Seed, Series A, Series B | Biotechnology, Health Care, Medical | $384k–$84M |
|
S.R.I.W.
VC Fund
|
15 | Belgium, United States, Spain | Series A, Series B | Health Care, Biotechnology, Manufacturing | $411k–$75M |
|
V-Bio Ventures
VC Fund
|
14 | Belgium, France, United States | Series A, Series B, Seed | Biotechnology, Health Care, Therapeutics | $3.1M–$88M |
|
Qbic Fund
VC Fund
|
12 | Belgium, The Netherlands | Seed, Series A | Biotechnology, Software, Health Care | $868k–$28M |
|
Capricorn Partners
VC Fund
|
12 | Belgium, The Netherlands, United States | Series A, Series B | Biotechnology, Software, Health Care | $3.3M–$42M |
|
Vives Louvain Technology Fund
VC Fund
|
10 | Belgium, France, United States | Series A, Series B | Health Care, Biotechnology, Medical | $491k–$125M |
|
VIB
VC Fund
|
10 | Belgium, Brazil, Denmark | Series A, Series B, Seed | Biotechnology, Health Care, Therapeutics | $3.1M–$84M |
|
Newton Biocapital
VC Fund
|
9 | Belgium, Japan, France | Series A, Seed | Biotechnology, Medical, Health Care | $2.7M–$84M |
|
Limburgse Reconversie Maatschappij
VC Fund
|
9 | Belgium, United States, The Netherlands | Seed, Series A | Information Technology, Software, Biotechnology | $494k–$11M |
|
WING by Digital Wallonia
VC Fund
|
9 | Belgium | Seed, Series A, Convertible Note | Software, Health Care, Information Technology | $219k–$11M |
|
Inventures SA
VC Fund
|
8 | Belgium, France, United Kingdom | Series A, Seed | Health Care, Biotechnology, Manufacturing | $82k–$13M |
|
Sambrinvest
VC Fund
|
8 | Belgium, France, Spain | Seed, Series A, Series B | Biotechnology, Health Care, Medical | $411k–$46M |
|
White Fund
VC Fund
|
7 | Belgium, United States | Seed, Series A, Venture - Series Unknown | Health Care, Medical, Medical Device | $4.1M–$12M |
|
EQT Life Sciences
VC Fund
|
7 | United States, The Netherlands, Switzerland | Series A, Series B, Series C | Biotechnology, Health Care, Therapeutics | $6.9M–$165M |
|
Vesalius Biocapital Partners
VC Fund
|
6 | Belgium, Germany, France | Series A, Series B, Series C | Biotechnology, Health Care, Medical | $3.8M–$100M |
|
Spinventure
VC Fund
|
6 | Belgium | Series A | Health Care, Biotechnology, Medical | $768k–$15M |
|
KBC
VC Fund
|
6 | Belgium, United States, The Netherlands | Seed, Series A, Series B | Biotechnology, Health Care, FinTech | $549k–$65M |
|
Gimv
VC Fund
|
6 | Belgium, United States, France | Series B, Series A | Biotechnology, Health Care, Medical | $3.3M–$79M |
|
SFPIM
VC Fund
|
5 | Belgium, France, Switzerland | Series A, Venture - Series Unknown | Biotechnology, Health Care, AgTech | $8.6M–$251M |
|
imec.istart Future Fund
VC Fund
|
5 | Belgium, United Kingdom | Seed, Pre-Seed, Series A | Health Care, Medical Device, Satellite Communication | $1.2M–$5.7M |
|
Droia Ventures
VC Fund
|
4 | United States, Belgium, The Netherlands | Series A, Series B, Series C | Biotechnology, Medical, Therapeutics | $15M–$125M |
|
Fund+
VC Fund
|
4 | Belgium, United States, Spain | Series A, Series B, Series C | Biotechnology, Health Care, Therapeutics | $11M–$401M |
|
Boehringer Ingelheim Venture Fund
VC Fund
|
4 | United States, Germany, Switzerland | Series A, Series B, Seed | Biotechnology, Health Care, Therapeutics | $1.8M–$50M |
|
HERAN Partners
VC Fund
|
4 | United Kingdom, Belgium, The Netherlands | Series A, Seed | Health Care, Artificial Intelligence, Hospital | $2M–$23M |
|
Omnes Capital
VC Fund
|
4 | France, Germany, United States | Series A, Series B | Software, Biotechnology, Health Care | $3.5M–$53M |
|
Kurma Partners
VC Fund
|
4 | France, Switzerland, Spain | Series A, Seed, Series B | Health Care, Biotechnology, Medical | $2.3M–$95M |
|
Mérieux Equity Partners
VC Fund
|
4 | France, United States, Belgium | Series A, Private Equity | Health Care, Biotechnology, Medical Device | $5.7M–$150M |
|
New Science Ventures
VC Fund
|
4 | United States, United Kingdom, Belgium | Series B, Series A, Series D | Biotechnology, Health Care, Medical | $4M–$52M |
|
Ackermans & van Haaren
VC Fund
|
3 | Belgium, India, Germany | Series B, Seed, Series A | Health Care, Medical, Biotechnology | $3M–$72M |
|
Miles Ahead
VC Fund
|
3 | Belgium, Ireland, United Kingdom | Seed, Pre-Seed | Software, Big Data, Robotics | $1M–$3.3M |
|
Spreds
VC Fund
|
3 | Belgium, France | Series A, Seed, Series B | Information Technology, E-Commerce, Health Care | $165k–$2.5M |
|
WE International
VC Fund
|
3 | Belgium, United States, France | Seed, Series A, Venture - Series Unknown | Health Care, Energy, Biotechnology | $2.2M–$251M |
|
Be Angels
VC Fund
|
3 | Belgium, France, Luxembourg | Seed, Pre-Seed | SaaS, Software, Health Care | $78k–$1.5M |
|
imec.xpand
VC Fund
|
3 | Belgium, United States, Germany | Seed, Series A, Series B | Semiconductor, Manufacturing, Medical Device | $3.3M–$100M |
|
TCD Capital
VC Fund
|
3 | Belgium, France | Series A, Series B, Seed | Biotechnology, Health Care, Medical Device | $2.2M–$18M |
|
Qbic
VC Fund
|
3 | Belgium | Seed, Series B | Health Care, Biotechnology, AgTech | $3.7M–$12M |
|
Forbion Capital Partners
VC Fund
|
3 | United States, United Kingdom, The Netherlands | Series B, Series A, Series C | Biotechnology, Health Care, Medical | $16M–$176M |
|
Volta Ventures
VC Fund
|
3 | Belgium, The Netherlands, United States | Seed, Series A, Pre-Seed | Software, Information Technology, Artificial Intelligence | $850k–$10M |
|
AdBio partners
VC Fund
|
3 | France, Spain, Belgium | Seed, Series A | Biotechnology, Health Care, Pharmaceutical | $2.2M–$37M |
|
Buysse & Partners
VC Fund
|
3 | Belgium, United Kingdom, The Netherlands | Series A, Seed | Software, Cloud Computing, FinTech | $1.1M–$11M |
|
b2venture
VC Fund
|
3 | Germany, Switzerland, United Kingdom | Series A, Seed, Series B | Software, Health Care, Information Technology | $1.3M–$52M |
|
Fountain Healthcare Partners
VC Fund
|
3 | Ireland, United States, France | Series A, Series B, Series C | Health Care, Biotechnology, Medical | $3.3M–$110M |
|
Thuja Capital
VC Fund
|
3 | The Netherlands, Belgium, United States | Series A, Seed | Biotechnology, Medical, Health Care | |
|
Theodorus III
VC Fund
|
3 | Belgium, Canada, France | Seed, Series A | Health Care, Life Science, Biotechnology | $2.2M–$18M |
|
Namur Invest
VC Fund
|
3 | Belgium, United States | Series A, Seed | Health Care, Medical Device, Auctions | $658k–$18M |
|
Novo Holdings
VC Fund
|
3 | United States, Denmark, United Kingdom | Series A, Series B, Series C | Biotechnology, Health Care, Medical | $9M–$135M |
|
BioGeneration Ventures
VC Fund
|
3 | The Netherlands, United States, Belgium | Series A, Seed | Biotechnology, Therapeutics, Health Care | $1.1M–$86M |
|
GoBeyond
VC Fund
|
3 | Switzerland, Germany, United Kingdom | Seed, Series A | Information Technology, Medical, Software | $544k–$10M |
| Access all 376 VC funds in Belgium Health Care startups. | |||||
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!Investor list
Do and dare company
Show more...Investment focus
- Industry: Software, Biotechnology, Health Care
- Stage:Series A, Seed
- Geography: Belgium, United States, The Netherlands
Investor stats
- Total investments: 152
- Round size: Seed $549k–$4.3M; Series A $2.7M–$40M
- Lead/follow: 22% lead, 78% follow
Portfolio highlights
- Animab — Animal Health Company
- Sentea — Sentea makes fibre optic Sensing affordable to the industry and enables continuous monitoring even in harsh environments.
- CHILI publish — Allow users to edit customizable documents, or fully automate artwork generation. Output files are ready to use for print and digital.
Noshaq offers financial services to help businesses develop.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Series A, Seed
- Geography: Belgium, France, Germany
Investor stats
- Total investments: 77
- Round size: Seed $137k–$6M; Series A $3.3M–$16M
- Lead/follow: 9% lead, 91% follow
Portfolio highlights
- TrustUp — TrustUp is the home contractors platform, connects homeowners with verified quality home improvement.
- Le Fourgon — Le Fourgon provides contained drinks for home delivery. They offer milk, water, beer, wine, fruit juice, and sodas. They allow customers to have their drinks delivered free of charge during the day.
- Allegro Biotech — Allegro has developed the world’s-first custom-tailored, durable, biocompatible, anisotropic, regenerative meniscus cartilage, providing immediate support while also leverage the body’s own healing potential to regenerate human cartilage (proliferation and differentiation of fibrochondrocyte cells).
Gemma Frisius Fund KU Leuven is a seed capital fund that aims to stimulate the creation and growth of university related spin-off companies.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Seed, Series A, Series B
- Geography: Belgium, France, United Kingdom
Investor stats
- Total investments: 39
- Round size: Seed $384k–$4.6M; Series A $932k–$84M; Series B $4.4M–$24M
- Lead/follow: 10% lead, 90% follow
Portfolio highlights
- Runeasi — The first scientifically validated wearable solution to measure impact while running and detect how your body responds to it - Perform real-time biomechanical assessments - Guide your athletes and patients with actionable insights to help them run more efficiently and recover from injuries with confidence
- Aspect Analytics — Aspect Analytics offers consultancy services, home-grown software, development of workflows, and customization of software.
- Magics Technologies — Magics Technologies is a nuclear research center that develops autonomous machines for sustainable energy sources.
The S.R.I.W. Group is an institution at the heart of the financial market that assists entrepreneurs in creating and developing businesses in the Walloon region. It reflects the effort of Wallonian industry in facing the challenges of the creation of economic value in the 21st century. Since its creation in 1979, the Société Régionaled’Investissement de Wallonie has continuously been expanding its abilities to adapt and anticipate as well as its flexibility in order to meet the requirements of its partners who are confronted with the evolution of the world economy. The principles of good governance, a strong business culture and shared values at the heart of the Group constitute important assets to capture the changing realities of the market and progress in a sustainable development perspective.
Show more...Investment focus
- Industry: Health Care, Biotechnology, Manufacturing
- Stage:Series A, Series B
- Geography: Belgium, United States, Spain
Investor stats
- Total investments: 111
- Round size: Series A $411k–$31M; Series B $1.6M–$75M
- Lead/follow: 21% lead, 79% follow
Portfolio highlights
- Univercells — We are biotech innovators, rooted in Belgium, driven by one purpose: To transform how biotech drugs are made so everyone, everywhere, can get them.
- Intressa Vascular — Intressa Vascular provides innovative solutions to address life-threatening cardiovascular conditions such as aortic dissection.
- Santero Therapeutics — This is the homepage of the website
V-Bio Ventures is an independent venture capital firm specialized in building and financing young, innovative life science companies. The fund invests throughout Europe in start-up and early-stage companies with high growth potential focusing on technologies that provide transformational improvements in the biotech, pharmaceutical and agriculturalsectors.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Therapeutics
- Stage:Series A, Series B, Seed
- Geography: Belgium, France, United States
Investor stats
- Total investments: 43
- Round size: Seed $3.1M–$50M; Series A $6.6M–$70M; Series B $12M–$88M
- Lead/follow: 35% lead, 65% follow
- Last fund: May invest from a new fund soon — raised $129M in 2021
Portfolio highlights
- Animab — Animal Health Company
- Step Pharma — Step Pharma is a spin-off of Imagine Institute stemming from Pr. Alain Fischer’s research on genetic immunodeficiencies. Step Pharma is a joint venture between Imagine, a research and innovative healthcare institute, Sygnature Discovery, a leading provider of integrated drug discovery resource and expertise, and Kurma Partners, a major player inthe funding of healthcare and biotechnology in Europe.
- Biodol Therapeutics — Biodol Therapeutics, founded in 2015, develops first-in-class compounds for the treatment of chronic pain (CP). Biodol Therapeutics has identified the Receptor Tyrosine Kinase (RTK) FLT3 as a key player for triggering and maintaining the chronic neuropathic pain (NP) state. New findings from Biodol Therapeutics' academic partnership (CyrilRivat and Jean Valmier at the INSERM Institute for Neurosciences in Montpellier) also demonstrated that FLT3 inhibition increases the potency of opioids for their analgesic effect, and hereby reduces their safety risks, especially addiction risk, which will help fighting the Opioid Crisis. The development of extracellular inhibitors of the FLT3 receptor, is a proprietary and key approach developed by Biodol Therapeutics.
The Qbic Fund is a multi-sector fund supporting spin-off companies of the Ghent, Brussels and Antwerp university associations and of VITO. Through its strategic partnership with the universities of Ghent, Brussels and Antwerp, and VITO, the Qbic Fund has early and privileged access to promising research projects at these partner universities. Ourinvestment approach is based on early in-depth and independent review and analysis followed by hands on involvement and support.In May 2012 the Qbic Fund held its first close and currently it has over € 30 million under management. The Qbic Fund is backed by several public and private investors and managed by Qbic Venture Partners.
Show more...Investment focus
- Industry: Biotechnology, Software, Health Care
- Stage:Seed, Series A
- Geography: Belgium, The Netherlands
Investor stats
- Total investments: 57
- Round size: Seed $1.3M–$7.7M; Series A $868k–$28M
- Lead/follow: 28% lead, 72% follow
- Last fund: Likely still investing — raised $57M in 2022
Portfolio highlights
- Aloxy — Aloxy offers reliable IIot solutions tailored to the needs of the process industry. Our valve sensor provides an open and close indication of manual valves.
- Accelleran — Accelleran is pioneering a disruptive approach to the delivery of cost-effective, carrier and mission-critical grade TDD and FDD Small Cell networks through its focus on software quality and partnerships with volume manufacturers.Accelleran provides LTE Small Cell software and LTE Small Cell product solutions which address the real-worldchallenges of volume deployment of Small Cells. We offer turnkey solutions and unique experience on the challenges of integrating cellular technology on low cost, yet powerful platforms and architectures. Accelleran offers its customers solid and dependable system solutions, backed by the support of our unparalleled expertise.Accelleran’s technology is genuinely independent from any HW platform and enables operators to invest once in the integration and validation of a common software base that can be deployed across different segments, platforms and Small Cell architectural approaches to enable a truly integrated HetNet.
- Blue Foot Membranes — Blue Foot Membranes delivers unbreakable MBR membranes for wastewater treatment. Reliable water reuse, high capacity and low total cost of ownership.
Capricorn Partners is a unique independent manager of venture capital, growth capital and quoted equity funds
Show more...Investment focus
- Industry: Biotechnology, Software, Health Care
- Stage:Series A, Series B
- Geography: Belgium, The Netherlands, United States
Investor stats
- Total investments: 118
- Round size: Series A $3.3M–$18M; Series B $5.3M–$42M
- Lead/follow: 32% lead, 68% follow
- Last fund: Likely actively investing — fund raised in 2025
Portfolio highlights
- Sensolus — Sensolus provides care-free tracking of your valuable non-powered assets directly from the cloud.Sensolus offers turnkey solutions for wireless, low-power context-aware sensing. Sensolus developed a personal product line of low-power tracker systems called STICKNTRACK.Sensolus is built upon many years of expertise in low-power networks,wireless sensor design, cloud-based sensor management, analytics, and applications.
- Delft Advanced Biorenewables — We enable the bio-economy by improving the productivity of fermentations with our in-situ product recovery (ISPR) technology.
- Trillium Renewable Chemicals — Trillium Renewable Chemicals manufactures chemicals from renewable feedstocks used in a variety of industrially important applications. The company was founded in 2021 and based in Knoxville, Tennessee.
Vives is an interregional seed and early stage technology multi-sector fund. The new fund, initiated by UCLouvain, is a unique European inter-university fund having access to world class innovations from leading EU top universities.
Show more...Investment focus
- Industry: Health Care, Biotechnology, Medical
- Stage:Series A, Series B
- Geography: Belgium, France, United States
Investor stats
- Total investments: 25
- Round size: Series A $491k–$46M; Series B $4.4M–$125M
- Lead/follow: 4% lead, 96% follow
- Last fund: May invest from a new fund soon — raised $37M in 2020
Portfolio highlights
- BOTALYS — BOTALYS uses an innovative Biomimetic Indoor Farming technology to recreate the ideal wild conditions for rare botanicals to grow in. We develop pristine & potent botanical ingredients for the Nutraceutical and Cosmetic industries.
- Sunrise — Sunrise aims to bring simple answers to millions of people suffering from sleep disorders.We have developed a 3-gram sensor to diagnose sleep with gold standard quality. The technology offers a revolutionary new way to measure brain commands at night, with published clinical results never seen before. Studies demonstrate Sunrise is as accurate asin-lab sleep studies, at a fraction of the cost.Affecting one in three people, sleep disorders are extremely common. Sleep apnea is the most prevalent disease with almost 1 billion persons concerned. This condition leads to great body damage over time and yet remains undiagnosed in 80% of the cases.Patients, caregiver and insurers stand to benefit greatly from a solution to current highly cumbersome, expensive and time-consuming diagnostics systems.
- Novadip Biosciences — Novadip Biosciences, an advanced biopharmaceutical company focused on new generation of therapies from adipose stem cells adapted to hard and soft tissues reconstruction.
Strategic research in on life sciences and biotechnology
Show more...Investment focus
- Industry: Biotechnology, Health Care, Therapeutics
- Stage:Series A, Series B, Seed
- Geography: Belgium, Brazil, Denmark
Investor stats
- Total investments: 25
- Round size: Seed $3.1M–$11M; Series A $6.8M–$84M; Series B $4.4M–$65M
- Lead/follow: 0% lead, 100% follow
Portfolio highlights
- Biotalys — Biotalys is an Agricultural Technology (AgTech) company that employs its proprietary Agrobody technology platform to develop crop and food protection products. The company develops a new generation of protein-based biocontrol solutions, shaping the future of sustainable and safe food supply. Biotalys' unique protein-based biocontrols combinethe high-performance characteristics of chemicals with the clean safety profile of biologicals, making them ideal crop protection agents for both pre- and post-harvest applications.It was incorporated in 2013 and is based in the Biotech hub in Ghent, Belgium.
- MRM Health NV — MRM Health NV, is a biopharmaceutical company focused on the discovery and development of innovative therapeutics based on the human microbiome. MRM Health was incorporated early 2020 by MRM Technologies, a Center of Expertise for microbiome research based in the biotech cluster in Ghent, in a joint venture with the Flemish Institute ofBiotechnology (VIB), an excellence-based entrepreneurial life sciences research institute in Flanders, Belgium, that focuses on translating basic scientific results into pharmaceutical, agricultural and industrial applications.
- Rainbow Crops — Rainbow Crops is a next-generation Agtech company developing climate-resilient, high-performing crop varieties.
Our mission is to mature innovation and support the growth of our portfolio companies to create value for patients, society, local ecosystems, and investors.
Show more...Investment focus
- Industry: Biotechnology, Medical, Health Care
- Stage:Series A, Seed
- Geography: Belgium, Japan, France
Investor stats
- Total investments: 22
- Round size: Seed $2.7M–$3.2M; Series A $6.1M–$84M
- Lead/follow: 68% lead, 32% follow
- Last fund: Likely still investing — fund raised in 2022
Portfolio highlights
- Bioxodes — Bioxodes is a clinical-stage biopharmaceutical company dedicated to the development of novel therapeutics to prevent thrombotic events without hemorrhagic risk.
- Tensegrity Pharma — Tensegrity Pharma is the developer of a novel drug designed to minimize bottlenecks and provide innovative value to patients.
- Augustine Therapeutics — Augustine Therapeutics is developing selective, safe and efficacious HDAC6 inhibitors designed for treatment of neuromuscular, neurodegenerative and cardiometabolic diseases. Discover our pipeline poised for clinical impact.
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!Oxygen for growth - LRM
Show more...Investment focus
- Industry: Information Technology, Software, Biotechnology
- Stage:Seed, Series A
- Geography: Belgium, United States, The Netherlands
Investor stats
- Total investments: 91
- Round size: Seed $494k–$5.2M; Series A $1.6M–$11M
- Lead/follow: 13% lead, 87% follow
Portfolio highlights
- Monsana — Monsana offers an AI-powered platform that connects eligible participants to relevant clinical trials throughout Europe.
- ADLC — ADLC employs drone technology to deliver logistics services, allowing businesses to implement drone-based solutions without having to manage them in-house. The company is focused on enhancing last-mile delivery in maritime and offshore environments. ADLC now conducts drone delivery services in the Port of Antwerp in collaboration with SGS, atesting and certification company, and works with companies such as BASF. Its drones have reduced delivery times and environmental effect, boosting efficiency sixfold and lowering CO2 emissions by up to 80% for petrochemical sample deliveries.
- Aidoptation — Aidoptation develops autonomous driving technology for dual-use applications in commercial automotive, police and first-responder vehicles, and defence-relevant environments.
W.IN.G by Digital Wallonia invests in SAAS, advanced tech and deep tech startups (AI, drones, medtech, IOT,...). W.IN.G brings smart money by helping startups by bi-weekly interactions and providing an operating teams (seasonal entrepreneurs being hands-on with the portfolio).
Show more...Investment focus
- Industry: Software, Health Care, Information Technology
- Stage:Seed, Series A, Convertible Note
- Geography: Belgium
Investor stats
- Total investments: 34
- Round size: Seed $346k–$1.9M; Series A $1.1M–$11M; Convertible Note $219k–$555k
- Lead/follow: 26% lead, 74% follow
Portfolio highlights
- IONNYK — IONNYK is a new medium of art photography, containing millions of tiny ink capsules.
- MYOCENE — Myocene is a Liège-based sports technology company which creates unique and innovative devices for measuring muscle fatigue and performance.
- Soil Capital Belgium — Discover Europe's first certified, multi-national carbon farming programme that rewards regenerative agriculture.
Inventures is a European venture capital fund that builds a better world through a portfolio of investments in sustainable businesses.The firm has two funds: Inventures I & Inventures II.Inventures was created to support early stage smart and innovative European businesses, to support sustainable job growth and empower entrepreneurs.Inventures empowers citizenship co-investments through a crowdfunding platform, MyMicroInvest.
Show more...Investment focus
- Industry: Health Care, Biotechnology, Manufacturing
- Stage:Series A, Seed
- Geography: Belgium, France, United Kingdom
Investor stats
- Total investments: 46
- Round size: Seed $82k–$2.2M; Series A $411k–$13M
- Lead/follow: 9% lead, 91% follow
- Last fund: May invest from a new fund soon — last raise in 2016
Portfolio highlights
- BiOceanOr — BiOceanOr harnessed the power of Marine Biology and AI to deliver bio-guided services that optimize fish welfare and fish growth, while supporting aquaculture sustainability standards
- myskillcamp — Myskillcamp is a digital learning platform and educational design support service. Myskillcamp supports their customers in the digital transformation of their company and the launch of their Digital Learning project. From the audit of needs to the design of engaging educational devices, through a pilot phase, they make a point of honor to adapt thedigital to the specificities of each and give it meaning.With their online platform, businesses can manage their learner communities and connect all their partners in one place. Their tool also allows businesses to structure training spaces by skills, trades, brands within camps. In parallel, businesses can create educational content from scratch, select a map in their marketplace, or plan sessions in-class. Businesses can organize the distribution of their training to a single learner or to a whole group.
- Octave — A sustainable, cost-effective and reliable energy storage system with second-life batteries from electric vehicles.
Sambrinvest is an active venture capital player in the region of Charleroi - Thuin.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Seed, Series A, Series B
- Geography: Belgium, France, Spain
Investor stats
- Total investments: 39
- Round size: Seed $544k–$24M; Series A $411k–$46M; Series B $4.4M–$44M
- Lead/follow: 10% lead, 90% follow
Portfolio highlights
- Sunrise — Sunrise aims to bring simple answers to millions of people suffering from sleep disorders.We have developed a 3-gram sensor to diagnose sleep with gold standard quality. The technology offers a revolutionary new way to measure brain commands at night, with published clinical results never seen before. Studies demonstrate Sunrise is as accurate asin-lab sleep studies, at a fraction of the cost.Affecting one in three people, sleep disorders are extremely common. Sleep apnea is the most prevalent disease with almost 1 billion persons concerned. This condition leads to great body damage over time and yet remains undiagnosed in 80% of the cases.Patients, caregiver and insurers stand to benefit greatly from a solution to current highly cumbersome, expensive and time-consuming diagnostics systems.
- Vertical Compute — Vertical Compute offers chiplet-based technology that cuts data movement to achieve up to 80% energy savings.
- Enodia Therapeutics — Enodia Therapeutics pioneers targeted protein degradation at the Sec61 translocon, developing small-molecule therapies for inflammatory and autoimmune diseases.
For game changers in medtech
Show more...Investment focus
- Industry: Health Care, Medical, Medical Device
- Stage:Seed, Series A, Venture - Series Unknown
- Geography: Belgium, United States
Investor stats
- Total investments: 12
- Round size: Seed $4.1M–$11M; Series A $5.3M–$12M; Venture - Series Unknown $5.5M–$11M
- Lead/follow: 67% lead, 33% follow
- Last fund: May invest from a new fund soon — raised $23M in 2019
Portfolio highlights
- neuroClues — An easy-to-use eye-tracking environment to help practitioners instantaneously quantify their clinical exam
- Minze Health — Digital Urology Starts Here from symptom to solution Home-based digital diagnostics and therapeutics for Male LUTS/BPH and OAB. Shaping the future of urology through meaningful data. Get In Touch Our Mission We're redefining how Male LUTS/BPH and OAB are diagnosed and treated Today's Challenge Lower urinary tract symptoms (LUTS) affect a growing group of patients.
- Clouds of care — Increasing your probability of success through the adoption of meaningful endpoints, starting from electrophysiology.
Providing capital plus strategic, clinical, operational, financial, and commercial support to deliver the added value inventors seek.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Therapeutics
- Stage:Series A, Series B, Series C
- Geography: United States, The Netherlands, Switzerland
Investor stats
- Total investments: 182
- Round size: Series A $6.9M–$77M; Series B $12M–$110M; Series C $12M–$165M
- Lead/follow: 41% lead, 59% follow
- Last fund: Likely still investing — raised $266M in 2023
Portfolio highlights
- LUMA Vision — OneProjects is an Irish-German cardiac imaging specialist.
- Neurent Medical — Discover NEUROMARK, a minimally invasive solution for Chronic Rhinitis that targets the posterior nasal nerve to provide lasting symptom relief.
- Rotation Medical — Rotation Medical Inc. manufactures and markets a collagen scaffold for rotational cuff disease in Minnesota. The company was formerly known as Denali Medical Inc. and changed its name to Rotation Medical Inc. in March 2010. Rotation Medical was founded in 2009 and headquartered in Plymouth, Minnesota.
Vesalius Biocapital Partners invests in companies active in human health through venture capital funds raised since 2007. They have contributed to developing 20 companies since inception.With more than € 150 million under management in two funds. Vesalius Biocapital Partners plays the role of lead investor in the large majority of its financingrounds.Their companies are based in Europe allowing easy interaction with management.They invest in all stages of development and do not shy away from relatively early-stage projects with a sound proprietary technology and corresponding IP, unique team skills and a clear competitive edge based on solid data.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Series A, Series B, Series C
- Geography: Belgium, Germany, France
Investor stats
- Total investments: 61
- Round size: Series A $3.8M–$20M; Series B $4.4M–$27M; Series C $7M–$100M
- Lead/follow: 43% lead, 57% follow
- Last fund: Likely still investing — fund raised in 2023
Portfolio highlights
- Nutrium — Nutrium is the most up-to-date nutrition software for dietitians and nutritionists to manage their nutrition business with nutritional assessment, meal planning and progress tracking.
- ENYO Pharma — ENYO Pharma is a biopharmaceutical company incorporated in Jan, 2014, by four scientists of the Infectiology Research Center in Lyon, France, and three seeding partners (2 privates and 1 public).The company is based in the Infectiology Center of Lyonbiopôle in Lyon, France and maintains tight collaborations with the seminal Inserm team and theBSL4 laboratory Inserm-Jean Mérieux.ENYO Pharma has licensed several Inserm patents issued from the discoveries of the founding scientists and developed a unique platform for the identification of intracellular therapeutic targets and molecules.The company is developing treatments against the most important viruses and is thriving to become a global leader in anti-virals. Research and Development is currently focused on human infecting viruses, with the first two programs being dedicated to the treatment of severe and seasonal flu and chronic hepatitis B. The company plans to conduct its molecules to Phase II clinical trials.
- Inflammatix — Inflammatix develops rapid point of care diagnostic tests by reading the immune system, and resolves major clinical health challenges.
Spinventure supports the creation of spin-off companies that aim to industrialize and commercialize the result of scientific research. Spinventure was born from a collaboration between MEUSINVEST and the University of Liège. It is headquartered in Angleur, Belgium.
Show more...Investment focus
- Industry: Health Care, Biotechnology, Medical
- Stage:Series A
- Geography: Belgium
Investor stats
- Total investments: 6
- Round size: Series A $768k–$15M
- Lead/follow: 0% lead, 100% follow
Portfolio highlights
- Dim3 — Improve patients outcome - Deliver actionable insights - Save healthcare costs
- Elysia — Elysia developed solution dedicated to quality control laboratories for the production of Radio Pharmaceuticals.
- Convert Pharmaceuticals — Convert Pharmaceuticals develops prodrugs that are inert upon administration to patients, but transform into potent anti-cancer agents upon entering tumors.
KBC Private Equity - the investment company of KBC Group - provides development capital and finances buy-outs to medium-sized companies in Belgium and in Central and Eastern Europe, KBC's home markets.Boasting an experienced team of 28 people, it has more than 60 active investments in portfolio with a market value in excess of EUR 400million.KBC Private Equity aims to become one of the leading private equity providers on KBC Group's home markets. As an active shareholder with a long-term perspective, KBC Private Equity is involved in taking strategic decisions and providing support to management teams.
Show more...Investment focus
- Industry: Biotechnology, Health Care, FinTech
- Stage:Seed, Series A, Series B
- Geography: Belgium, United States, The Netherlands
Investor stats
- Total investments: 33
- Round size: Seed $549k–$8.2M; Series A $2.9M–$65M; Series B $33M–$44M
- Lead/follow: 24% lead, 76% follow
Portfolio highlights
- Rookoo — Rookoo is an AI-driven venue management software that talks to your customers, handles the intake, checks availability, fills your CRM or booking software, and hands off to your team for seamless follow-up.
- Qivalis — Qivalis is a financial technology company designed for payments, settlements, and financial services.
- Ion Beam Applications — Ion Beam Applications is a Belgium-based company that develops and markets technologies, pharmaceutical products and tailored solutions for the healthcare sector, with emphasis on cancer diagnosis and therapy. IBA is also active in the sterilization and ionization field. The Company operates through two business segments, namely the pharmaceuticalssegment, which includes radiopharmaceuticals and the equipments segment, which encompasses proton therapy, particle accelerators and dosimetry.
Gimv, a trusted European investment company, helps mid-market businesses create sustainable value through growth capital and expertise across diverse sectors.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Series B, Series A
- Geography: Belgium, United States, France
Investor stats
- Total investments: 169
- Round size: Series A $3.3M–$79M; Series B $7M–$69M
- Lead/follow: 32% lead, 68% follow
- Last fund: May invest from a new fund soon — raised $622M in 2010
Portfolio highlights
- spineart — Spineart is a privately held medical device company focused on simplifying the surgical act by designing, developing and promoting safe and efficient solutions to spine surgeons, operating room teams, and patients.
- ImCheck Therapeutics — ImCheck Therapeutics is a developer of immuno-modulatory antibodies designed for the treatment of cancer and other immune-related diseases. The company's services are engaged in the discovery and development of immunomodulators for treating breast cancer, gastric, ovarian cancer cells and other solid solid tumours.
- Anjarium Biosciences — Pioneering the next generation of non-viral gene therapy - by tackling more diseases, more precisely and in a more personalized way.
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!SFPIM investment firm that invests in technology and infrastructure.
Show more...Investment focus
- Industry: Biotechnology, Health Care, AgTech
- Stage:Series A, Venture - Series Unknown
- Geography: Belgium, France, Switzerland
Investor stats
- Total investments: 25
- Round size: Series A $8.6M–$57M; Venture - Series Unknown $11M–$251M
- Lead/follow: 32% lead, 68% follow
Portfolio highlights
- banqUP — BanqUP is an API-driven platform for open banking solutions, allowing for banks and fintech companies to access a number of European banking APIs. BanqUP helps TPPs and banks quickly access open banking ecosystem and analyze banking data, allowing them to create bold and innovative solutions, as well as cross-sell and up-sell their existingproducts.
- D-CRBN — CO2 recycling for industrials
- Biotalys — Biotalys is an Agricultural Technology (AgTech) company that employs its proprietary Agrobody technology platform to develop crop and food protection products. The company develops a new generation of protein-based biocontrol solutions, shaping the future of sustainable and safe food supply. Biotalys' unique protein-based biocontrols combinethe high-performance characteristics of chemicals with the clean safety profile of biologicals, making them ideal crop protection agents for both pre- and post-harvest applications.It was incorporated in 2013 and is based in the Biotech hub in Ghent, Belgium.
Early-stage venture capital fund focused on alumni of the imec.istart accelerator and exceptional tech founders building in Applied AI, Spacetech, Healthtech, and Deep Tech. Based in Antwerp, Belgium.
Show more...Investment focus
- Industry: Health Care, Medical Device, Satellite Communication
- Stage:Seed, Pre-Seed, Series A
- Geography: Belgium, United Kingdom
Investor stats
- Total investments: 10
- Round size: Seed $1.2M–$5.7M
- Lead/follow: 30% lead, 70% follow
Portfolio highlights
- EDGX — EDGX, founded in 2023 in Ghent, is a Belgian Space Tech company developing high-speed edge computing units for satellites. Its NVIDIA-powered Sterna Computer and SpaceFeather software enable real-time, AI-driven on-orbit data processing for applications in communication, Earth observation, and intelligence.
- nxgsat — through software-defined satellite communication modems based on the 3GPP 5G NR NTN standard
- OnTracx — OnTracx combines wearable technology and intelligent load management software to support runners and professionals to avoid running injuries & return to run safely.
Droia Ventures is a specialist investor, dedicated to making an impact and save patient lives. We invest in the most promising life science companies.
Show more...Investment focus
- Industry: Biotechnology, Medical, Therapeutics
- Stage:Series A, Series B, Series C
- Geography: United States, Belgium, The Netherlands
Investor stats
- Total investments: 39
- Round size: Series A $15M–$75M; Series B $29M–$89M; Series C $75M–$125M
- Lead/follow: 33% lead, 67% follow
- Last fund: May invest from a new fund soon — raised $241M in 2021
Portfolio highlights
- Actio Biosciences — At Actio, we are leveraging advances in genetics and precision medicine to develop life-changing treatments that target underlying shared biology between rare and common diseases. We are applying expertise in genetics, drug discovery, and data sciences to pinpoint targets that not only cause rare diseases with high unmet need, but that also hold promise in more common indications.
- Protego Biopharma — Protego Biopharma develops therapeutics based on the clear human genetic link, excellent human safety profile, proof-of-principle efficacy. The company was founded in 2011 and is headquartered in San Diego, California.
- Unnatural Products — Unnatural Products is a startup pairing AI with chemistry to create treatments for drug targets. Its AI-enhanced technology platform creates entirely new drugs by engineering passively permeable, macrocyclic peptides that access traditionally undruggable targets.Unnatural Products was founded in 2017 and is headquartered in Santa Cruz,California.
Fund+ is a venture capital firm that invests in companies operating in the diagnostics, therapeutics, medical devices, and life science sectors. The firm wants to create sustainable shareholders' value, contribute to the development of a leadership position in the life sciences sector, and generate a tangible, beneficial societal impact.Fund+ was established in 2015 and is based in Leuven, Belgium.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Therapeutics
- Stage:Series A, Series B, Series C
- Geography: Belgium, United States, Spain
Investor stats
- Total investments: 32
- Round size: Series A $11M–$44M; Series B $21M–$125M; Series C $11M–$401M
- Lead/follow: 28% lead, 72% follow
Portfolio highlights
- Ona Therapeutics — Ona Therapeutics is a biotech company that specializes in the discovery and development of therapeutic biologics targeting tumor metastatic-initiating cells and lipid metabolism. Founded in 2019 by Salvador Aznar-Benitah and Valerie Vanhooren, it was a spin-off from ICREA and Advanced Studies, and the IRB Institute for Research in Biomedicine.
- Tubulis — Reimagining Antibody Drug Conjugates Tubulis generates uniquely matched protein-drug conjugates through the combination of novel proprietary technologies and disease-specific biologic insight. Our goal is to expand the therapeutic potential of antibody-drug conjugates (ADCs) by increasing design flexibility while overcoming constraints of toxicity, efficacy and indication. Tubulis will build new conjugates to fill its pipeline and
- TargED Biopharmaceuticals — TargED Biopharmaceuticals is a biotechnology company that develops first-in-class biological drugs to improve treatment of thrombosis.TargED stands for Targeted Enzyme Delivery. Their biological drugs are unique by using small antibodies (“VhH”) to deliver enzymes to sites of thrombosis, enabling ‘targeted’ thrombolysis.
Discover Boehringer Ingelheim Venture Fund. We invest in groundbreaking science to transform care. Explore our mission and join us in advancing medicine
Show more...Investment focus
- Industry: Biotechnology, Health Care, Therapeutics
- Stage:Series A, Series B, Seed
- Geography: United States, Germany, Switzerland
Investor stats
- Total investments: 101
- Round size: Seed $1.8M–$20M; Series A $3.8M–$34M; Series B $11M–$50M
- Lead/follow: 48% lead, 52% follow
- Last fund: May invest from a new fund soon — raised $250M in 2018
Portfolio highlights
- Perfood — Perfood is a digital therapeutic startup that identifies what actions need to take on a personalized level, to prevent or fight diseases. Using sensors, lab results, and holistic analyses, they derive therapeutic angles and deliver them in a slick, easy-to-use way, making them accessible for all patients. They call this approach digitaltherapeutics. A digital solution that is just as effective as a drug. But without side effects.
- ArrePath — ArrePath is an anti-infective drug discovery company addressing the global health challenge of drug resistant infections.
- Brainomix — Since launching as a spin-out from the University of Oxford in 2010, Brainomix has developed award-winning, AI-powered imaging biomarkers, assisting physicians across the world to make better life-saving decisions. Brainomix seminal product, e-Stroke is a collection of tools that use state-of-the-art AI algorithms to support doctors by providingreal-time interpretation of brain scans to help guide treatment and transfer decisions for stroke patients, allowing more patients to get the right treatment, in the right place, at the right time.
HERAN PARTNERS is a Belgian-based investment fund founded by Annie Vereecken together with Katleen Vandersmissen, Joris Mortelmans and Herman Verrelst within the sector of MedTech and Digital Health. With a clear focus on European HealthTech, the fund provides venture & growth capital accompanied by a strong network, expertise and mentorship tostartups and scale-ups with a strong technology platform and market potential.
Show more...Investment focus
- Industry: Health Care, Artificial Intelligence, Hospital
- Stage:Series A, Seed
- Geography: United Kingdom, Belgium, The Netherlands
Investor stats
- Total investments: 12
- Round size: Seed $2M–$8.1M; Series A $12M–$23M
- Lead/follow: 42% lead, 58% follow
Portfolio highlights
- Pharmacelera — Improving pharmaceutical R+D productivity through a lean drug discovery process based on advanced computational methodologies.
- Hypervision Surgical — Making surgeries more precise, safer and faster. Guiding the future of surgery using AI-powered hyperspectral imaging.
- Broken String Biosciences — The next generation of genome-wide on- and off-target analysis in your own hands. Our INDUCE-seq platform provides precise off-target detection and genome-wide insights.
Omnes VC is the Venture Capital arm of Omnes Capital, a leading private equity firm dedicated to energy transition and innovation with €4.8 billion in assets under management and a 20 year + experience in: venture capital, buyout & growth capital, private debt, renewable energy, co-investment, secondary funds of funds. Omnes Capital is fullyindependent.With 65 business sales including 14 IPOs carried out in 16 years, Omnes VC is one of the key players in France in financing innovative SMEs with expertise in both Technology and Healthcare sectors. Omnes VC has supported 120 companies and has invested more than €500M in businesses such as Scality, Novaled, BioVex, arGEN-X, Pixium, Blablacar.
Show more...Investment focus
- Industry: Software, Biotechnology, Health Care
- Stage:Series A, Series B
- Geography: France, Germany, United States
Investor stats
- Total investments: 181
- Round size: Series A $3.5M–$44M; Series B $4.4M–$53M
- Lead/follow: 27% lead, 73% follow
- Last fund: May invest from a new fund soon — raised $403M in 2020
Portfolio highlights
- VSORA — VSORA provides high performance companion solutions combining AI and signal processing to enable autonomous driving and ADAS
- SeqOne Genomics — Healthcare is undergoing a revolution, known as genomic medicine, that uses the patient’s genomic information to optimise treatment. This trend is accelerating thanks to the arrival of New Generation Sequencing (NGS) techniques that have reduced the cost of decoding genomic material while increasing the amount useful data obtained. However, NGShas had only limited impact on mainstream healthcare due to the difficulties in analyzing more and richer genomic data. SeqOne’s mission is to provide tools that enable the healthcare industry to analyse NGS genomic data better and more cost-effectively to provide universal access to genomic medicine.
- Complix — Complix is a biopharmaceutical company focused on the discovery and development of Alphabodiesâ„¢, a novel class of biopharmaceuticals that offer significant advantages over existing protein based therapies. Alphabodiesâ„¢ bind with high affinity to a wide range of disease targets and are particularly suited to address certain targets that aredifficult to reach with antibodies or other types of protein scaffolds. Due to their unique stability and versatility Alphabodiesâ„¢ can be delivered via alternative non-injectable routes of administration, unlike most therapeutic proteins.
Kurma Partners is a management company based in Paris, specializing in the financing of innovation in healthcare and biotechnology, from pre-creation to development capital. Kurma Partners, which manages the Kurma Biofund I, II funds and the Kurma Diagnostics fund, is one of the main players in the financing of therapeutic and medical innovationsin Europe, particularly through links with many institutes. research and prestigious hospitals.
Show more...Investment focus
- Industry: Health Care, Biotechnology, Medical
- Stage:Series A, Seed, Series B
- Geography: France, Switzerland, Spain
Investor stats
- Total investments: 138
- Round size: Seed $2.3M–$17M; Series A $3.8M–$95M; Series B $12M–$72M
- Lead/follow: 47% lead, 53% follow
- Last fund: Likely actively investing — fund raised in 2024
Portfolio highlights
- EvlaBio — EvlaBio is a biotech company focused on the development of drug programs that address significant unmet medical needs. The company's pipeline includes robust scientific antibody programs for the treatment of hepatocellular carcinoma (Phase 1 ready) and chronic kidney disease with left ventricular hypertrophy (pre-clinical).
- AM Pharma — AM-Pharma B.V., a biopharmaceutical company, engages in the development and commercialization of therapeutics for human use in the Netherlands. It focuses in the pre-clinical and clinical development of novel therapeutics to treat inflammatory and infectious diseases. The company develops products based on endogenous proteins and protein derivedpeptides, as well as molecules that naturally occur in the human body. Its products include alkaline phosphatase for treatment of acute kidney injury and ulcerative colitis; and immune response amplifying peptide hLF1-11 for the treatment of drug resistant hospital acquired infections. The company was founded in 2000 and is headquartered in Bunnik, the Netherlands.
- DAMAE Medical — Damae Medical is a Paris, France-based medtech company. It has developed a medical device capable of seeing biological tissues in depth, at a cellular level and in vivo. This innovative optical imaging technology will especially allow dermatologists to evaluate in a precise, efficient and rapid way malignancy of tumors by a simple contact with thesurface of the skin. DAMAE Medical’s mission is to put the great power of bio-photonics at the service of opening new opportunities in medical imaging and diagnosis.
Mérieux Equity Partners (“MxEP”) is a management company dedicated to venture, growth and LBO investments in the healthcare and nutrition sectors. MxEP actively supports entrepreneurs and industrial companies with differentiated products and services, by providing privileged access to its expertise and international network. MxEP currently managesmore than €600m AUM and has recently launched a new vehicle MP3 of €350m dedicated to growth/LBO.
Show more...Investment focus
- Industry: Health Care, Biotechnology, Medical Device
- Stage:Series A, Private Equity
- Geography: France, United States, Belgium
Investor stats
- Total investments: 57
- Round size: Series A $5.7M–$22M; Private Equity $22M–$150M
- Lead/follow: 37% lead, 63% follow
- Last fund: May invest from a new fund soon — raised $417M in 2020
Portfolio highlights
- DeepUll — DeepUll is a biotech company that focuses its activity on the development of a new diagnostic system for early-stage sepsis condition. DeepUll’s proposal is based on quickly identifying the pathogens and offering the antibiogram within a few hours on the one hand, and on using the data and learning about the patient’s immunological and functionalstatus on the other. The system allows doctors to predict the future appearance and evolution of sepsis within a short period of time and thus provide a suitable clinical response even before the symptoms arise.
- Ceva Santé Animale — Ceva Sante Animale S.A. engages in the research, development, production, and marketing of pharmaceutical products and vaccines for companion and farm animals. They work with welfare and social programmes around the world to bring this vision to life – anywhere their products and know-how can make a difference and with all kinds of partners. FromUganda, working with small-scale livestock owners and vets to stop sleeping sickness in its tracks, to the UK and USA, where they supply the biggest animal welfare charities with Adaptil® collars to help re-home shelter dogs.
- CorFlow Therapeutics — CorFlow Therapeutics is a medtech startup that develops proprietary technologies for diagnosis and treatment of microvascular obstructions in heart attack patients. The CorFlow technologies enable interventional cardiologists to diagnose and treat MVO in severe heart attack patients thereby potentially reducing the short- and long-term complicationrates in these patients.
New Science Ventures is a venture capital firm that focuses on investments in life sciences and information technology companies. They invest in early and late stage companies taking novel scientific approaches to address significant unmet needs, while creating order-of-magnitude improvements in performances. The company also invests in companiesusing science-based innovations to address market needs in life sciences such as pharmaceuticals, biologics, medical devices, diagnostics, and IT. The team of the company expertise in strategy and corporate planning, operations and cost management, and leadership development.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Series B, Series A, Series D
- Geography: United States, United Kingdom, Belgium
Investor stats
- Total investments: 85
- Round size: Series A $4M–$49M; Series B $8M–$52M; Series D $5M–$38M
- Lead/follow: 36% lead, 64% follow
- Last fund: May invest from a new fund soon — raised $4.9M in 2020
Portfolio highlights
- EXTEN Technologies — EXTEN HyperDynamic software platform solves the primary challenges of today's data centers: the necessity of keeping up with surging data density, velocity, and volume requirements, and the need for increased application agility.
- BrightVolt — BrightVolt is an innovative manufacturer of solid-state thin & flexible lithium polymer batteries and power-efficient thin & flexible microelectronics for IoT clients. It specializes in the fields of battery, electronics, and manufacturing. BrightVolt got recapitalization in November 13, 2013.
- Phase Four — Phase Four is a provider of electric propulsion (EP) for small satellites.The company was founded in 2015 to accelerate the advancement of its core differentiator, the Radio Frequency Thruster (RFT). The hallmark of Phase Four’s RFT is simplicity. Because the RFT omits a hollow cathode and high voltage electronics, three key improvements arerealized: 1) a 10x materials cost savings versus legacy EP systems, 2) a significant decrease in the size of power electronics, and 3) propellant agnosticism. In a first for EP, the Phase Four RF thruster accomplishes this while achieving performance in the same thrust, specific impulse (Isp), and efficiency class as legacy plasma propulsion solutions.
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!Ackermans & van Haaren is a diversified group active in 5 segments: Marine Engineering & Infrastructure; Private Banking; Real Estate, Leisure & Senior Care; Energy & Resources; Development Capital. Marine Engineering & Infrastructure: DEME, one of the largest dredging companies in the world - Algemene Aannemingen Van Laere,a leading contractor in Belgium. Ackermans & van Haaren is an independent and diversified group aiming at creating shareholder value through long-term investments in a limited number of companies with growth potential on an international level.
Show more...Investment focus
- Industry: Health Care, Medical, Biotechnology
- Stage:Series B, Seed, Series A
- Geography: Belgium, India, Germany
Investor stats
- Total investments: 18
- Round size: Seed $33M–$42M; Series A $8.4M–$15M; Series B $3M–$72M
- Lead/follow: 39% lead, 61% follow
Portfolio highlights
- Biotalys — Biotalys is an Agricultural Technology (AgTech) company that employs its proprietary Agrobody technology platform to develop crop and food protection products. The company develops a new generation of protein-based biocontrol solutions, shaping the future of sustainable and safe food supply. Biotalys' unique protein-based biocontrols combinethe high-performance characteristics of chemicals with the clean safety profile of biologicals, making them ideal crop protection agents for both pre- and post-harvest applications.It was incorporated in 2013 and is based in the Biotech hub in Ghent, Belgium.
- MRM Health NV — MRM Health NV, is a biopharmaceutical company focused on the discovery and development of innovative therapeutics based on the human microbiome. MRM Health was incorporated early 2020 by MRM Technologies, a Center of Expertise for microbiome research based in the biotech cluster in Ghent, in a joint venture with the Flemish Institute ofBiotechnology (VIB), an excellence-based entrepreneurial life sciences research institute in Flanders, Belgium, that focuses on translating basic scientific results into pharmaceutical, agricultural and industrial applications.
- DISCO Pharmaceuticals — DISCO Pharmaceuticals is a firm that specializes in large-scale surfaceome unlocking of cancer cells.
Miles Ahead is a Venture Studio that helps first-time founders of Deep Tech & AI startups to grow faster by producing and funding their business within an empowering environment.
Show more...Investment focus
- Industry: Software, Big Data, Robotics
- Stage:Seed, Pre-Seed
- Geography: Belgium, Ireland, United Kingdom
Investor stats
- Total investments: 11
- Round size: Seed $1M–$3.3M; Pre-Seed $1.1M–$2.3M
- Lead/follow: 64% lead, 36% follow
Portfolio highlights
- OTIV — OTIV offers autonomous technology to make your railway operations in complex environment safer and more efficient.
- DevAlly — AI Driven Accessibility Compliance Management
- TalentGuide — Unlock workforce potential with Talentguide's skills intelligence platform, transforming ambition into measurable ability through actionable insights and personalized development paths.
We empower high-potential entrepreneurship and democratize venture capital. Discover promising start-ups & SMEs and invest alongside business angels.
Show more...Investment focus
- Industry: Information Technology, E-Commerce, Health Care
- Stage:Series A, Seed, Series B
- Geography: Belgium, France
Investor stats
- Total investments: 15
- Round size: Seed $165k–$1.3M; Series A $247k–$2.5M; Series B $165k–$680k
- Lead/follow: 7% lead, 93% follow
Portfolio highlights
- Jelloow — Jelloow is a data-driven platform designed to help businesses clearly identify their true marketing needs. Instead of relying on assumptions or generic solutions, we analyze key data points to provide precise, tailored insights. Our approach eliminates guesswork, ensuring that companies invest in the right marketing strategies to achieve theirgoals. With Jelloow, businesses can confidently navigate their marketing landscape, knowing they’re making decisions backed by real data.The Jelloow process: 1. Plan, Scope and Post your project 2. Get pitches from Marketing Agencies 3. Select your team and start your project. Simple as it can be. Our Jelloow Leads are marketing experts, and will provide best practices so you can see results, ASAP. Get started with a (free!) planning call Let’s chat!
- Digiteal — Digiteal offers a wide range of services for e-invoice presentment, electronic payments and open banking.
- NietsCo — NietsCo. is the home of Botaniets Gin 0.0%, a leading selection of alcohol-free products, carefully distributed to the world's best restaurants, concept stores, shops and consumers.
WE International is a financial firm that provides an array of loans, funding, acquisition, and investment services.
Show more...Investment focus
- Industry: Health Care, Energy, Biotechnology
- Stage:Seed, Series A, Venture - Series Unknown
- Geography: Belgium, United States, France
Investor stats
- Total investments: 22
- Round size: Seed $2.2M–$43M; Series A $10M–$57M; Venture - Series Unknown $16M–$251M
- Lead/follow: 27% lead, 73% follow
Portfolio highlights
- neuroClues — An easy-to-use eye-tracking environment to help practitioners instantaneously quantify their clinical exam
- VolitionRx — Volition is a multi-national life sciences company developing simple, easy to use blood-based cancer tests to accurately diagnose a range of cancers. The tests are based on the science of Nucleosomics, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid which is an indication that disease ispresent.As cancer screening programs become more and more widespread, its products aim to help to diagnose a range of cancers quickly, simply, accurately, and cost-effectively. Early diagnosis has the potential to not only prolong the life of patients but also to improve their quality of life.Volition's research and development activities are currently centered in Belgium, with additional offices in London, Texas, and Singapore, as the company focuses on bringing its diagnostic products to market first in Europe, then in the U.S. and worldwide.
- Vertical Compute — Vertical Compute offers chiplet-based technology that cuts data movement to achieve up to 80% energy savings.
Early stage Entrepreneurs Coaching and FinancingOne of Europe's leading Business Angels Networks. We connect innovative growth companies to equity finance and coaching by experienced angel investors. The network is 250 members strong and has been assisting innovative entrepreneurs to find financing for more than 10 millions Euros in thelast 4 years.
Show more...Investment focus
- Industry: SaaS, Software, Health Care
- Stage:Seed, Pre-Seed
- Geography: Belgium, France, Luxembourg
Investor stats
- Total investments: 24
- Round size: Seed $247k–$1.5M; Pre-Seed $78k–$373k
- Lead/follow: 38% lead, 62% follow
Portfolio highlights
- ChainComply — ChainComply provides enhanced KYT due diligence solutions for banks and VASPs and relieves them from stressing over incoming transfers from crypto exchanges. ChainComply develops a SaaS tool that scans the client's crypto exchange and blockchain transaction history to reveal the source of funds of crypto holders. The company solutionsimplifies complex transaction streams, and then it identifies high-risk transactions and patterns, enabling AML teams to understand their clients better and meet regulatory obligations efficiently.
- NIUM — NIUM is a startup focused on personalized nutrition and gut microbiome research. NIUM created science-based solutions to transform nutrition research and product development.
- TalentGuide — Unlock workforce potential with Talentguide's skills intelligence platform, transforming ambition into measurable ability through actionable insights and personalized development paths.
Expanding nanotechnology into business.
Show more...Investment focus
- Industry: Semiconductor, Manufacturing, Medical Device
- Stage:Seed, Series A, Series B
- Geography: Belgium, United States, Germany
Investor stats
- Total investments: 52
- Round size: Seed $3.3M–$23M; Series A $8.7M–$56M; Series B $12M–$100M
- Lead/follow: 48% lead, 52% follow
- Last fund: Likely still investing — raised $351M in 2024
Portfolio highlights
- Pharrowtech — Pharrowtech designs next-generation solutions for fixed-wireless access, wireless VR/AR and ultra-high capacity wireless links. It builds on more than 12 years of top-notch R&D performed at imec, the Belgian R&D powerhouse. Leveraging deep technical expertise in algorithm, chip and antenna design for millimeter-wave systems, it createsproducts with best-in-class performance, power and cost features.
- Spectricity — Spectricity provides multispectral imaging solutions to enhance color accuracy and analysis capabilities in mobile and consumer electronics.
- Swave Photonics — Swave develops Spatial Computing, Holography, holographic chips, and holograms in the HXR chip to create 3D augmented and virtual reality and HUD Heads Up Displays
TheClubDeal is an investment holding and fund manager co-investing into SME’s and real estate projects. It provides facilitation of governance between non-executive shareholders and entrepreneurs. Its governance structure, including its charter of avoidance of conflict of interests, is therefore paramount to the adequate management of the Company.At TheClubDeal, we connect Investors and Entrepreneurs around promising investment opportunities. For each of these, we will invest ourselves and co-invest with a selected number of investors. We add value by processing strong applied governance principles, when selecting and managing our investments, and by gathering the necessary skills to successfully grow the businesses and real-estate projects we co-invest in. TheClubDeal is launching their second fund, a 50M € PRIVAK/PRICAF in H1 2021 with the mandate to invest in Belgian scale-ups in three sectors: Smart Living, Tech and Life Sciences.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical Device
- Stage:Series A, Series B, Seed
- Geography: Belgium, France
Investor stats
- Total investments: 17
- Round size: Series A $2.2M–$7.7M; Series B $12M–$18M
- Lead/follow: 24% lead, 76% follow
Portfolio highlights
- Vaxinano — Vaxinano is a biotechnology company specialized in preclinical and pharmaceutical development of human and veterinary vaccines and drug delivery systems. Vaxinano was created in 2016, building on 25 years of research and clinical trials on vaccines and the patented technology of Pr Didier Betbeder.
- Inpulse — Inpulse is an automated supply management platform for restaurateurs.
- Clouds of care — Increasing your probability of success through the adoption of meaningful endpoints, starting from electrophysiology.
Qbic is the result of a lot of thinking, debating and sketching of what a city hotel could be; one that breaks the rules and makes people smile.An astonishing level of change has swept through the world over the last few years. But the hotel experience is no different than it’s ever been: stuffy, over-priced and lacking soul. They’re here tochange all that. they’re curious, imaginative and friendly, and they think there are lots of people just like us seeking a hotel with personality in the middle of the city.They believe in something better than what’s currently out there. A place that celebrates life rather than sucks life out of it. A hotel that’s built on creativity and a belief that you don’t have to accept the conventional. Somewhere that sends you away with fun stories and ideas, and is easy on your pocket.
Show more...Investment focus
- Industry: Health Care, Biotechnology, AgTech
- Stage:Seed, Series B
- Geography: Belgium
Investor stats
- Total investments: 7
- Round size: Seed $3.7M–$11M; Series B $7.5M–$12M
- Lead/follow: 0% lead, 100% follow
Portfolio highlights
- moveUP — Ontvang medische zorg op afstand voor en na uw operatie. moveUP is gespecialiseerd in de begeleiding van knie- en heupoperaties.
- Axithra — Axithra provides therapeutic medication monitoring and measures beta-lactam antibiotic concentrations in blood.
- Cascador Health — Cascador Health bridges the gap between sources and users of healthcare data. Using curated, validated and anonymized RWD allows healthcare providers and life science industry to gain insights and provide better care.
Impacting the future of medicine.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Series B, Series A, Series C
- Geography: United States, United Kingdom, The Netherlands
Investor stats
- Total investments: 200
- Round size: Series A $19M–$176M; Series B $16M–$155M; Series C $19M–$113M
- Lead/follow: 52% lead, 48% follow
- Last fund: Likely actively investing — fund raised in 2024
Portfolio highlights
- Azafaros — Azafaros aims at developing therapeutic agents for the treatment of rare metabolic disorders such as lysosomal storage disorders through oral administration of azasugar compounds. These novel, very promising agents were discovered by Professor Hans Aerts at Leiden University and Amsterdam UMC and are exclusively licensed to Azafaros.
- Inflazome — Situs gacor premium Megawin188 paling banyak di minati oleh semua kalangan karena pecah selayar tanpa henti dan memiliki tampilan yang sangat memanjakan mata.
- Beacon Therapeutics — Beacon aids in restoring and improving the vision of patients with ophthalmic gene therapy. Find out more.
Volta Ventures is a venture capital firm that offers seed & early stage VC for internet & software companies in the Benelux.The fund’s team, with active support from some 30 business angels, expects to make a substantial impact on every company it invests in by working with the founders and management to identify new markets andcustomers, hire senior talent, provide ongoing guidance and arrange further financing rounds.Volta Ventures has offices in Ghent and Amsterdam.
Show more...Investment focus
- Industry: Software, Information Technology, Artificial Intelligence
- Stage:Seed, Series A, Pre-Seed
- Geography: Belgium, The Netherlands, United States
Investor stats
- Total investments: 90
- Round size: Seed $850k–$4.4M; Pre-Seed $1M–$3M; Series A $2.2M–$10M
- Lead/follow: 49% lead, 51% follow
- Last fund: May invest from a new fund soon — raised $72M in 2019
Portfolio highlights
- Nodalview — Nodalview helps real estate agents deliver cutting edge content and an impressive buying experience for happy and loyal customers.
- RESPONSUM — RESPONSUM is the EU's most user-friendly privacy management SaaS solution. Become compliant with GDPR or any other privacy regulation easily.
- CHILI publish — Allow users to edit customizable documents, or fully automate artwork generation. Output files are ready to use for print and digital.
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!AdBio partners is a European Life Sciences Venture Capital firm dedicated to seeding healthcare’s step forward.We work with leading research institutions and well-established technology transfer offices, with a strong network of scientific and medical partners, exploring new territories to source breakthrough medical discoveries and driveinventive Life Sciences start-ups to success.We embrace European Life Sciences’ dynamic of innovation. Europe harbors a vibrant environment for medical and scientific investigation, with some of the most leading-edge academic and research centers. AdBio partners seizes the opportunity to highlight their undervalued research programs and assets and participate in structuring Europe’s biotechnology ecosystem.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Pharmaceutical
- Stage:Seed, Series A
- Geography: France, Spain, Belgium
Investor stats
- Total investments: 32
- Round size: Seed $2.2M–$18M; Series A $18M–$37M
- Lead/follow: 41% lead, 59% follow
- Last fund: Likely still investing — raised $116M in 2021
Portfolio highlights
- Orikine Bio — Orikine Bio is a pioneer biotech company in the field of tailored cytokines with unmatched biological properties for the treatment of immune-mediated disorders.
- ARTHEx Biotech — ARTHEx Biotech S.L. is a spin-off company of the University of Valencia that is developing advanced RNA treatments against genetic diseases.
- Integra Therapeutics — Integra Therapeutics is a developer of next generation of gene editing tools to cure diseases.
Buysse and Partners is a private equity investment group based in Antwerpen that offers smart equity, a growth fund, and partnerships.
Show more...Investment focus
- Industry: Software, Cloud Computing, FinTech
- Stage:Series A, Seed
- Geography: Belgium, United Kingdom, The Netherlands
Investor stats
- Total investments: 6
- Round size: Seed $1.1M–$2M; Series A $3.9M–$11M
- Lead/follow: 50% lead, 50% follow
- Last fund: May invest from a new fund soon — raised $23M in 2012
Portfolio highlights
- Twikit — Deliver unforgettable customer experiences with real time 3D product configurators, linked to your existing order and manufacturing flows.
- Bluebee — Delivering a streamlined way for users to analyze, explore, and manage large-scale genomics data in the cloud.
- moonbird — Slow breathing is the easiest way to relieve stress and promote relaxation. Moonbird and moonbuddy make it intuitive and easy to practice slow breathing exercises.
B2venture is a venture capital firm focused on early-stage investments in digital and industrial technology companies. B2venture invests EUR 100m+ per year in high-growth companies with ticket sizes from EUR 0.25m to 3.5m.
Show more...Investment focus
- Industry: Software, Health Care, Information Technology
- Stage:Series A, Seed, Series B
- Geography: Germany, Switzerland, United Kingdom
Investor stats
- Total investments: 235
- Round size: Seed $1.3M–$9M; Series A $4M–$22M; Series B $8M–$52M
- Lead/follow: 29% lead, 71% follow
- Last fund: Likely still investing — raised $135M in 2021
Portfolio highlights
- Kiin Bio — Drug discovery is a system problem, where every inefficiency amplifies the next. We have the solution.
- Kubermatic — Easily manage multiple Kubernetes clusters with the automation power of the Kubermatic platform. Scale your business with reliability.
- Calvin Risk — We help companies manage the risks of their AI algorithms!
Fountain Healthcare Partners is an Irish based life science venture capital fund. Fountain is exclusively focused on the life science sector. Specific areas of interest to them are: specialty pharma, medical devices, biotechnology and diagnostics. They will deploy the majority of their capital in Europe with a strong focus on Ireland.
Show more...Investment focus
- Industry: Health Care, Biotechnology, Medical
- Stage:Series A, Series B, Series C
- Geography: Ireland, United States, France
Investor stats
- Total investments: 50
- Round size: Series A $6.6M–$43M; Series B $5.5M–$68M; Series C $3.3M–$110M
- Lead/follow: 42% lead, 58% follow
- Last fund: May invest from a new fund soon — raised $128M in 2019
Portfolio highlights
- Palyon Medical — Palyon Medical Corporation is a medical device company developing technologies for the treatment of chronic pain, spasticity and other neurological diseases.
- Neuromod Devices — Neuromod is a medical device company formed to advance the science of bi-modal neuromodulation.We are committed to delivering treatments that significantly reduce the suffering of underserved patient populations who live with chronic and debilitating conditions globally. Our goal is to design products that empower patients to take control oftheir own treatment, delivering targeted therapies that integrate seamlessly into a modern lifestyle.Neuromod has developed and patented a bi-modal neuromodulation technology that it is evaluating for neurological disorders including chronic tinnitus, a condition affecting 10% of the adult population and commonly known as 'ringing in the ears'.
- Ermium Therapeutics — Ermium Therapeutics is a biotech company developing innovative therapies for auto-immune diseases, based on a breakthrough discovery showing that CXCR4 is a master regulator of inflammation.Ermium Therapeutics was founded in June 2019 by Jean-Philippe HERBEUVAL, Kurma Partners, Idinvest Partners, Domain Therapeutics and Erganeo. The company isbased in Paris and has signed a worldwide exclusive license agreement on intellectual property from CNRS and University Paris Descartes (France) through an agreement with Erganeo, which supported the maturation of the project in an academic setting. In addition, Ermium Therapeutics recently won the innovation i-Lab 2019 award from the French Ministry of Research and Higher Education.
Thuja Capital invests in early stage medical product innovations for diagnosis, cure, care or prevention.
Show more...Investment focus
- Industry: Biotechnology, Medical, Health Care
- Stage:Series A, Seed
- Geography: The Netherlands, Belgium, United States
Investor stats
- Total investments: 54
- Lead/follow: no public data
Portfolio highlights
- Pan Cancer — Pan Cancer T is an immunotherapy company developing next-generation TCR-T cell therapies for solid cancer.
- Synerkine Pharma — Synerkine Pharma. Connecting Cytokines for the benefit of patients.
- Artica Therapeutics — Artica Therapeutics specializes in biotechnological research and development for medical devices, pharmaceutical processes, and food.
Theodorus is the spin-off fund of Université Libre de Bruxelles that invests ininvest in early stage projects based on proprietary disruptive technologies.
Show more...Investment focus
- Industry: Health Care, Life Science, Biotechnology
- Stage:Seed, Series A
- Geography: Belgium, Canada, France
Investor stats
- Total investments: 15
- Round size: Seed $3.7M–$18M; Series A $2.2M–$6.6M
- Lead/follow: 20% lead, 80% follow
Portfolio highlights
- DrugBank — DrugBank augments human intelligence to improve the world’s health. Our suite of products are powered by the world’s most complete and up-to-date pharmaceutical knowledge database. It includes everything there is to know about drugs and how they work in the body. We enable companies to improve healthcare delivery through precision medicine orclinical software applications, as well as uncover insights through data science in drug discovery. Our knowledge base can be integrated into software solutions to help achieve clinical intelligence. Companies can easily scale their usage through our API and launch faster with flexible data modules. By providing users with advanced insights and the right information at the right time, users are empowered to make better health decisions.Our extensive, structured datasets are used to discover novel drug candidates, identify drug repurposing opportunities, and build predictive machine learning models. Companies working with data science can find answers quickly and get drugs to market faster with our evidence-based drug information. Lastly, our publicly available resource, DrugBank Online, is free-to-use with limited datasets available for download for academic and non-commercial researchers. DrugBank has been cited in over 13,000 academic publications and is used by millions of researchers and health professionals globally.
- Simmunome AI — We use AI to create accurate, comprehensive disease models using multi-omic data to determine the probability of success of a drug. Our clinical trial simulations allow you to gain insights, make go/no-go decisions, and de-risk your pipeline, getting you to market faster and reducing your R&D co
- Ability biologics — Ability develops innovative, targeted, immune modulating biotherapeutics to address unmet medical needs in patients with cancer and autoimmune diseases.
Namur Invest Group provides companies with financing solutions in various forms adapted to their needs, to strengthen their financial.
Show more...Investment focus
- Industry: Health Care, Medical Device, Auctions
- Stage:Series A, Seed
- Geography: Belgium, United States
Investor stats
- Total investments: 7
- Round size: Series A $658k–$18M
- Lead/follow: 14% lead, 86% follow
Portfolio highlights
- Invineo — Invineo design and development of a "smart machine" for catering and hospitality professionals.
- VolitionRx — Volition is a multi-national life sciences company developing simple, easy to use blood-based cancer tests to accurately diagnose a range of cancers. The tests are based on the science of Nucleosomics, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid which is an indication that disease ispresent.As cancer screening programs become more and more widespread, its products aim to help to diagnose a range of cancers quickly, simply, accurately, and cost-effectively. Early diagnosis has the potential to not only prolong the life of patients but also to improve their quality of life.Volition's research and development activities are currently centered in Belgium, with additional offices in London, Texas, and Singapore, as the company focuses on bringing its diagnostic products to market first in Europe, then in the U.S. and worldwide.
- Sunrise — Sunrise aims to bring simple answers to millions of people suffering from sleep disorders.We have developed a 3-gram sensor to diagnose sleep with gold standard quality. The technology offers a revolutionary new way to measure brain commands at night, with published clinical results never seen before. Studies demonstrate Sunrise is as accurate asin-lab sleep studies, at a fraction of the cost.Affecting one in three people, sleep disorders are extremely common. Sleep apnea is the most prevalent disease with almost 1 billion persons concerned. This condition leads to great body damage over time and yet remains undiagnosed in 80% of the cases.Patients, caregiver and insurers stand to benefit greatly from a solution to current highly cumbersome, expensive and time-consuming diagnostics systems.
Novo Holdings is a world-leading life science investor with a focus on creating long-term value.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Series A, Series B, Series C
- Geography: United States, Denmark, United Kingdom
Investor stats
- Total investments: 351
- Round size: Series A $9M–$125M; Series B $13M–$135M; Series C $30M–$118M
- Lead/follow: 40% lead, 60% follow
- Last fund: May invest from a new fund soon — raised $165M in 2018
Portfolio highlights
- Biosyntia — Biosyntia is a biotech startup within synthetic biology and metabolic engineering. We develop biocatalysts at an unprecedented speed and efficiency by employing our patent pending high-throughput screening technology.By developing tailored processes based on biocatalysis, Biosyntia enables production of complex chemical compounds byfermentation. Biocatalysis may substantially reduce both production costs and environmental impact compared to other processes such as chemical synthesis. We partner with manufacturers of fine chemical compounds (flavors, fragrances, APIs, pigments, additives, intermediates, and more) in order to establish more sustainable manufacturing processes for a greener tomorrow.Biosyntia is located at the Novo Nordisk Foundation (NNF) Center for Biosustainability in Hørsholm, 25 kilometers north of Copenhagen.
- IVERIC bio — IVERIC bio is a science-driven biopharmaceutical company focused on the discovery and development of novel treatment options for retinal diseases with significant unmet medical needs. The Company is currently developing both therapeutic product candidates for age-related retinal diseases and gene therapy product candidates for orphan inheritedretinal diseases.
- Nkarta Therapeutics — Nkarta seeks to improve upon the efficacy of cell therapy, making it more potent, better tolerated and more rapidly available to a broad population of patients with a variety of hematologic and solid tumor malignancies.While T-cell therapy, often known as CAR-T, has proven successful in certain cancer indications, its promise has been limited toa few hematologic malignancies and the side effects can be severe. Natural Killer cells are the immune system’s first responders against diseases and pathogens. Unlike T cells, they have an inherent ability to target tumor cells without genetic alteration, and therefore hold significant promise in the development of potent therapies that can be used more readily for diverse tumor types. Nkarta’s differentiated cell therapy approach is designed to boost and enhance the inherent power of Natural Killer cells to target and destroy tumor cells, while also offering a better tolerated safety profile.
Shaping new life-science ventures.
Show more...Investment focus
- Industry: Biotechnology, Therapeutics, Health Care
- Stage:Series A, Seed
- Geography: The Netherlands, United States, Belgium
Investor stats
- Total investments: 63
- Round size: Seed $1.1M–$50M; Series A $5.3M–$86M
- Lead/follow: 29% lead, 71% follow
- Last fund: May invest from a new fund soon — raised $148M in 2021
Portfolio highlights
- Dualyx — Dualyx engages in the discovery and development of biologicals for the treatment of autoimmune and rare diseases.
- Azafaros — Azafaros aims at developing therapeutic agents for the treatment of rare metabolic disorders such as lysosomal storage disorders through oral administration of azasugar compounds. These novel, very promising agents were discovered by Professor Hans Aerts at Leiden University and Amsterdam UMC and are exclusively licensed to Azafaros.
- Complement Therapeutics — Turning powerful new Complement System insights into innovative treatments Developing the next generation of complement medicines [chevron-down] Turning powerful new Complement System insights into innovative treatments Developing the next generation of complement medicines [chevron-down] Geographic atrophy (late dry age-related macular degeneration) is a chronic eye condition that affects millions - and for which there is
GoBeyond is a FinTech company transforming angel investing into a new scalable asset class for small and large, novice to experienced investors. It offers a unique deal platform, portfolio tools, syndication/pooling, due diligence, investment monitoring services, training and certified deal leaders.Its clients are individuals, familyoffices, professional groups and corporations. It is active in the EU, Switzerland and the US. GoBeyond also offers educational training modules for angel investors in 11 categories.
Show more...Investment focus
- Industry: Information Technology, Medical, Software
- Stage:Seed, Series A
- Geography: Switzerland, Germany, United Kingdom
Investor stats
- Total investments: 163
- Round size: Seed $544k–$5M; Series A $1.2M–$10M
- Lead/follow: 4% lead, 96% follow
Portfolio highlights
- Fastree3D — Fastree3D imaging sensors help recognize and measure distance to fast moving objects in real-time, enabling driving assistance or autonomous navigation. Fastree3D SA is a fabless semiconductor company, spin-off from EPFL Lausanne, Switzerland founded in September 2013 (UID CHE-291.330.490). The company subsidiary Fastree3D B.V. performs researchwith TU-Delft, Netherlands (KvK 58866973).
- Spyra One — Single Shot Technology | Tactical display | Automatic Refill | Power Shot SpyraTwo - the world's strongest water gun! Start epic water battles with the only water gun in the world that features our patented Single-Shot-Technology, fully automatical pump, a hightech tactical display and the Power Shot for extra impact.
- DomoHealth — Join us in revolutionizing patient care using the power of AI-assisted digital health platform and safety solutions. Enhancing digital health with the best platform, application and devices for the direct benefits of patients and healthcare professionals.
Health Care VC funding in Belgium at a glance
Stats across 365 deals from 376 investors.
Access all 376 VC funds in Belgium Health Care startups.
Open ListFAQ
Is Shizune data fresh/accurate?
Shizune has monitored hundreds of funding sources since 2020.
Our investor database is updated every day, so investor data is always fresh.
All metrics are calculated from confirmed public rounds, so the data is accurate.
Can I download investor list?
To download the Health Care VC Funds in Belgium investor list, create a Shizune account. This investor list will be added to your saved investors and available for download in the export section.
You can also enrich the investor list with investor emails, phones, LinkedIns, and other contact data.
Can I access investor database?
To access all 376 VC funds investing in Belgium Health Care startups and 48,091+ more investors, create a Shizune account.
Shizune has a database of 48,091 investors. Our investor database is fresh and updated daily.
The Shizune investor database has information on investor investment focus, investor contact data, and full investor portfolio since 2020.
You can enrich with email and download the data.
Does Shizune have investor emails and contacts?
Shizune enriches investors with contact data that includes: email, phones, LinkedIn, socials, website, and others.
To guarantee the highest discovery rate, we search across 20+ contact search tools.
To maximize delivery rate and reduce bounce rate, we validate emails.
You can enrich your investor list with Shizune. Download it too.
What is Shizune?
Shizune is a 48,091 investor database updated daily.
With Shizune you can:
- browse the database
- use smart matching
- enrich with emails
- download
All you need to find investors for your startup.
Who is Shizune for?
Shizune is built for startup founders by startup founders.
If you are looking for funding for your startup, try the Shizune database — we have investors for every stage, industry, and country.
Is Shizune free?
Shizune is free forever. You can search and browse investors for free.
Email search and export are paid features.
For full info, visit our pricing.
Who built Shizune?
Shizune is built by founders with the goal of helping all founders raise funding no matter where they are.
Contact 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!